

RBXY IN INR C --

On 01 Apr d Vol 5,723,924 0 --

H --

-- / --

L --

-- X --

Val .00

RBXY IN Equity

25) Settings

26) Export

Security Ownership

Ranbaxy Laboratories Ltd

ISIN INE015A01028

1) Current 2) Historical 3) Matrix 4) Ownership 5) Transactions 6) Options

Search Name All Holders, Sorted by Size

21) Save Search

22) Delete Search

23) Refine Search

Text Search

Holder Group All Holders

Allocate Multi-Managed

Holder Name	Portfolio Name	Source	Opt	Position	% Out	Latest Chg	File Dt
		All	All				
1. DAIICHI SANKYO CO LTD	--	Co File		268,711,323	63.13	0	12/31/14
2. LIFE INSURANCE CORP OF IN	--	Co File		24,476,523	5.75	-1,935	12/31/14
3. SILVERSTREET DEVELOPERS	--	Co File		6,967,542	1.64	0	12/31/14
4. ORANGE MAURITIUS INVESTH	--	Co File		4,650,000	1.09	0	12/31/14
5. GIC PRIVATE LIMITED	--	Co File		4,624,096	1.09	81,869	12/31/14
6. HDFC LIFE INSURANCE CO LT	Multiple Portfolios	HF-AGG		2,706,978	0.64	16,061	02/28/15
7. JUPITER INV MGMT GROUP L	--	ULT-AGG		1,536,000	0.36	0	03/31/15
8. DIMENSIONAL FUND ADVISOR	Multiple Portfolios	HF-AGG		746,002	0.18	0	02/27/15
9. FIL LIMITED	--	ULT-AGG		707,253	0.17	233,269	03/31/15
10. BLACKROCK	--	ULT-AGG		373,069	0.09	5,000	03/31/15
11. EATON VANCE MANAGEMENT	Multiple Portfolios	HF-AGG		239,660	0.06	0	03/31/15
12. FIDELITY INV ASSET MGMT	Multiple Portfolios	HF-AGG		235,374	0.06	-84,008	12/31/14
13. VANGUARD GROUP INC	Multiple Portfolios	HF-AGG		225,651	0.05	-3,419,762	04/30/15
14. DAIVA ASSET MANAGEMENT S	Daiva India Stock Activ	IT-JPH		192,700	0.05	0	12/16/14
15. TIAA CREF INVESTMENT MAN	Multiple Portfolios	HF-AGG		190,518	0.04	900	03/31/15
16. CAISSE DE DEPOT ET PLACEN	CAISSE DE DEPOT ET PLACEN	CAH-PE		177,664	0.04	0	12/31/14
17. PICTET FUNDS	--	ULT-AGG		146,223	0.03	0	06/30/14
18. UBS AG	--	ULT-AGG		144,376	0.03	-748	01/31/15
19. CREDIT SUISSE AG	--	ULT-AGG		139,869	0.03	0	03/31/15
20. SJUNDE AP FONDEN	AP7 AKTIEFOND	HF-SVE		109,853	0.03	6,412	03/31/15
21. JULIUS BAER MULTICOOPERA	JULIUS BAER MULTISTOC	HF-LUX		84,780	0.02	20,000	01/31/15
22. SIMPLICITY AB	SIMPLICITY INDIEN	HF-SVE		77,000	0.02	77,000	03/31/15

% Out 74.79

SI % Out n/a

Zoom

85%

Australia 61 2 9777 8600 Brazil 5511 2395 9000 Europe 44 20 7330 7500 Germany 49 69 9204 1210 Hong Kong 852 2977 6000

Japan 81 3 3201 8900


Singapore 65 6212 1000

U.S. 1 212 318 2000

Copyright 2015 Bloomberg Finance L.P.

SN 636136 EDT GMT-4:00 G549-1295-0 28-May-2015 10:38:57

<HELP> for explanation, <MENU> for similar functions.



Ranbaxy Laboratories Limited manufactures and distributes a wide range of pharmaceutical products. The Company makes multisource antibiotics, analgesics, anti-inflammatory drugs and anti-ulcerant/gastrointestinal drugs such as "Roscollin" (Ampicillin), "Cifran" (Ciprofloxacin) and "Sporidex" (Cephalexin).



Px/Chg 1D (INR)	N.A./N.A.
52 Wk H (04/01/15)	869.7
52 Wk L (05/29/14)	430.05
YTD Change/%	N.A./N.A.
Mkt Cap (INR)	N.A.
Shrs Out/Float	425.7M/120.8M
Exch Float (11/29/2013)	169.3M

9) Earn (ERN)	10) Est (EE)
Date	(E) 05/29/15
P/E	C N.A.
Est P/E	03/15 N.A.
T12M EPS	(INR) N.A.
Est EPS	12.56
Est PEG	N.A.

Ind Gross Yield	N.A.
Round Lot	1

13) Corporate Info	
14) www.ranbaxy.com	
Gurgaon, India	
Empls 11,784 (03/31/14)	
15) Management (MGMT)	
16) Arun Sawhney	
CEO/Managing Director	
17) Indrajit Banerjee	
President/CFO	
18) Manjeet Bindra	
Chief Data Reliability Officer	
19) 12M Total Ret (TRA)	N.A.
20) Beta vs SENSEX	0.45

Page

RBXY IN Equity		98) Report		Page 2/5 Security Description	
1) Profile		2) Issue Info		3) Ratios	
4) Revenue & EPS		5) Industry Info			
6) Public Offerings (CACS)				8) Shareholdings (OWN)	
Follow-on Offering		03/17/06, Common Stock		Shares Outstanding	425.66M
Shares Offered		8.62M		Promoter Holding	268.71M
Share Price		INR 402.35		Indian/Foreign	0/268.7M
Lead Manager		UBS Securities India Pte Ltd		Public Holding	156.29M
				Inst./Non Inst.	89.9M/66.3M
				Foreign Holding	320.7M
				Total FII limit	30%
				Current FII	12.22%
9) Issue Information (RELS)				10) Eqty Wgts (WGT)	
Sec Type Common Stock		EDE15BP		N.A.	
Pri Exch Natl India		BESGPRO		N.A.	
PAR		BESGCOV		N.A.	
Pri MIC XNSE		BIGNRCGP		3.445%	
Incorp INDIA		BIGNRCGC		2.429%	
		SXBBMP		N.A.	
BBGID BBG000CYGQG9		SXABMP		N.A.	
ISIN INE015A01028		BIGNRCGT		19.838%	
		SEMGCPD		N.A.	
		BIGNRCAP		7.191%	
		Deriv/Mrgn			
		No Options Available			
				11) Top Holders (HDS)	
				as of 5/28/2015	
				DAIICHI SANKYO CO LTD	63.13%
				LIFE INSURANCE CORP...	5.75%
				SILVERSTREET DEVELOP...	1.64%
				ORANGE MAURITIUS IN...	1.09%
				GIC PRIVATE LIMITED	1.09%
				HDFC LIFE INSURANCE...	0.64%
				JUPITER INV MGMT GR...	0.36%

Page

RBXY IN Equity		98) Report		Page 3/5 Security Description	
1) Profile		2) Issue Info		3) Ratios	
Fiscal Year End		03/2014		7) Income Statements (FA IS)	
Last Quarter End		12/15 Q3		8) Balance Sheet (FA BS)	
Current/T12M		(INR)		9) Cash Flow (FA CF)	
Issue Data		Per Share Data		Cash Flow Analysis	
Last Px	INR/N.A.	EPS	N.A.	CF/Ni	N.A.
P/E	N.A.	EPS T12M	N.A.	Dvd P/O	N.A.
Dvd Ind Yld	N.A.	DPS	N.A.	Cash Gen/Cash Req	N.A.
P/B	N.A.	Bk Val Per Sh	78.03	Csh Dvd Cov	N.A.
P/S	N.A.	Rev/Bas Sh	N.A.	CFO/Sales	N.A.
P/CF	N.A.	Csh Earn / Sh	N.A.	Eff IR	N.A.
Mkt Cap	N.A.	Curr Shares Out	425.7M		
Curr P/FCF	N.A.	FCF/Basic Sh	N.A.		
Growth Potential		Profitability		Structure	
EPS - 1 Yr Gr	N.A.	OPM	N.A.	Curr Ratio	0.9
Cap 1Y Gr	4.5%	Pretax Mrgn	N.A.	Quick Ratio	0.5
BPS 1Y Gr	-5.7%	ROA	N.A.	Debt/Assets	47.2%
Retntn Rt	N.A.	ROE	N.A.	Debt/Com Eq	199.7%
Rev - 1 Yr Gr	N.A.	ROC	N.A.	A/R Trnovr	N.A.
Ast 1Y Gr	-2.1%	Ast TO	N.A.	Inv Turnover	N.A.
Empl 1Y Gr	N.A.	Finl Lev	4.2	GM	N.A.
		Eff Tx Rate	N.A.	EBIT/Tot Int Exp	N.A.

Page

RBXY IN Equity

98) Report

Page 4/5

Security Description

1) Profile

2) Issue Info

3) Ratios

4) Revenue & EPS

5) Industry Info

6) Comparable Revenue (EM)

7) Comparable Earnings Per Share (EM)

Year	Revenue (B)
2011	99.6
2012	122.5
2013	106.0
2014	-
2015	116.7
2016	124.6

(INR)	2011	2012	2013	2014	2015	2016
FY	99.6B	122.5B	106.0B		116.7B	124.6B

Year	EPS (INR)
2011	-68.81
2012	27.24
2013	-23.93
2014	-
2015	12.56
2016	20.14

(INR)	2011	2012	2013	2014	2015	2016
FY	-68.81	27.24	-23.93		12.56	20.14

Color Legend: Reported, Estimated

8) Geo Seg (FA GEO)

2014 Rev

3Yr Gr

9) Prod Seg (FA PROD)

2014 Rev

3Yr Gr

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Color Legend: Reported, Estimated

Australia 61 2 9777 8600 Brazil 5511 2395 9000 Europe 44 20 7330 7500 Germany 49 69 9204 1210 Hong Kong 852 2977 6000
 Japan 81 3 3201 8900 Singapore 65 6212 1000 U.S. 1 212 318 2000
 SN 636136 EDT GMT-4:00 G549-1295-0 28-May-2015 10:39:18
 Copyright 2015 Bloomberg Finance L.P.

RBXY IN INR C -- -- -- / -- -- x --
 On 01 Apr d Vol 5,723,924 0 -- H -- L -- Val .00

RBXY IN Equity	98) Report	Page 5/5	Security Description
1) Profile	2) Issue Info	3) Ratios	4) Revenue & EPS
			5) Industry Info

Critical Themes: Generic Pharma, Global

6) Primary Industry Dashboard (BIP)

7) Bloomberg Intelligence Biosimilars Survey

8) M&A: Teva Pounces for Mylan in Highly Accretive Deal

9) M&A: Perrigo-Mylan Deal

10) First Biosimilar Approval in U.S.

11) Industry Rev (CCB)	FY Rev	% Tot Rev	Industry Indicators	Latest
12 RANBAXY LABS LTD	122.53B	100.00%	18 Total U.S. Generic Unit Volume (USD)	294.52k
13 TEVA PHARMA	1.23T	100.00%	19 Total Final ANDAs Approved	414.00
14 ACTAVIS PLC	694.22B	87.11%	20 Tentative ANDAs Approved	97.00
15 NOVARTIS AG-REG	583.39B	18.24%		
16 MYLAN NV	471.82B	100.00%		

17) Company Revenue Breakdown (CCB)
Generic Pharma

100.00%

21) Op Stats (RV)	Co	Range of Comparables
Sales Growth Yoy (%)	N.A.	-2.06 42.31
EBITDA Margin (%)	N.A.	-184.2 44.76
Gross Margin (%)	N.A.	0.00 0.00

22) Eq Valuation (RV)	Co	Range of Comparables
Est P/E Current Yr	N.A.	21.49 31.86
Price/Book	N.A.	0.33 10.68

● Company Values for RBXY IN Equity ◆ Industry Peers Median

Australia 61 2 9777 8600 Brazil 5511 2395 9000 Europe 44 20 7330 7500 Germany 49 69 9204 1210 Hong Kong 852 2977 6000
 Japan 81 3 3201 8900 Singapore 65 6212 1000 U.S. 1 212 318 2000 Copyright 2015 Bloomberg Finance L.P.
 SN 636136 EDT GMT-4:00 G549-1295-0 28-May-2015 10:39:19

<HELP> for explanation, <MENU> for similar functions.
#<Go> to View Ratings Profile

RBXY IN Equity Company Tree Rating Alert Page 1/1 Credit Rating Profile

Ranbaxy Laboratories Ltd

1) Bloomberg Default Risk (DRSK)

CRISIL

2) Fixed Deposit FAAA

3) Short Term A1+

ICRA


4) Short Term NR

CARE

5) Long Term AAA

6) Short Term A1+

<HELP> for explanation, <MENU> for similar functions.
Enter all values and hit <Go>, <Pg Dn> for all maturities



Ticker: RBXY IN Equity

Periodicity: Annuals

Currency: INR

Note: Years shown on the report are Fiscal Years

Company: Ranbaxy Laboratories Ltd

Filing: Most Recent

Consolidation Basis: Consolidated Data

Corporate Finance Essentials (

	Original:2009 A	Original:2010 A	Restated:2011 A	Original:2012 A	Preliminary:2013 A	Original:2014 A	Current/LTM	Estimate:2015 A	Estimate:2016 A
For the period ending	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-3-31	2014-12-31	2015-3-31	2016-3-31
Revenue	75,970.36	89,607.71	99,700.02	122,528.94	106,041.92		106,139.72	116,660.09	124,628.60
EBITDA	7,243.97	18,742.62	12,844.13	17,079.95	9,070.13		14,412.87	14,776.92	17,302.10
Depreciation & Amortization	2,667.95	5,529.23	4,018.48	3,424.94	3,808.64		4,014.05		
Operating profit (loss)	4,576.02	13,213.39	8,825.65	13,655.01	5,261.49		10,398.82	11,910.25	20,140.33
Total interest expense	710.43	613.89	656.78	1,366.74	4,436.92		5,401.37		
Net profit (loss)	2,964.92	14,967.51	-2,517.29	9,227.64	-10,115.98		-8,115.53	3,603.90	8,276.10
Cash & Equivalents	14,247.83	32,628.03	30,518.39	45,959.52	14,523.62	15,515.65	20,782.62		
Total debt	36,345.00	43,818.69	44,907.29	49,013.04	59,647.70	65,978.62	60,034.60		
Total Debt Weighted Average Maturity									
Total Equity	43,967.14	56,694.28	29,503.48	41,732.78	35,964.82	33,888.75			
Chg in non-cash wc	270.64	2,987.26	19,450.11	7,029.47					
Capital Expenditures	-5,220.51	-4,983.41	-4,773.45	-4,767.10				-5,226.20	-5,667.75
Increase: LT Debt	15.17	1,748.18	4,023.41	10,196.38					
Decrease: LT Debt									
Inc(Dec) ST Debt	-2,830.91	6,697.49	12,840.44	-3,274.09					
Market cap.	217,755.19	252,056.02	170,867.68	212,504.31	192,060.97	154,636.98			
Minority Interest	533.22	647.12	809.66	889.52	945.68	858.10	791.78		
Eff tax rate	69.46	27.93		23.97					
Net Cash Paid for Acquisitions									
Net current assets	12,739.38	12,677.69	-4,190.29	10,468.85	-984.10	-5,402.90			
Op Lease - Current	840.25	860.61	922.92	924.85					
Op Lease - Yr 1	248.28	274.07	363.25	419.73		431.06			
Op Lease - Yr 2									
Op Lease - Yr 3									
Op Lease - Yr 4									
Op Lease - Yr 5									
Op Lease - Beyond yr 5	120.99	64.36	37.90	105.86		72.77			
Dividends Paid	0.00	-9.17	-979.44	0.00					
Dec capital stock	0.00	0.00	0.00	0.00					
Current Shares Outstanding	420.42	421.04	422.00	422.47	423.74	423.78	425.66		
Price per share	252.35	517.95	598.65	404.90	503.00	453.25	859.80		
Options Outstanding End Of Period	7.41	7.40	7.02	6.53	5.67	11.09			
Avg Exercise Price (Options Outstanding)									
R & D expenditures	4,943.82	4,978.90	4,702.07	4,490.41					
Consolidated Debt Weighted Average Maturity									
Op Lease - Years 2 - 5	537.65	576.08	740.48	803.48		627.66			

The format and content of this report may not be modified or altered (including, but not limited to, via deletion or addition) in any way. The BLOOMBERG PROFESSIONAL service and BLOOMBERG Data are owned and distributed locally by Bloomberg Finance L.P. ("BFLP") and its subsidiaries in all jurisdictions other than Argentina, Bermuda, China, India, Japan and Korea (the "BLP Countries"). BFLP is a wholly-owned subsidiary of Bloomberg L.P. ("BLP"). BLP provides BFLP with all global marketing and operational support and service for the Services and distributes the Services either directly or through a non-BFLP subsidiary in the BLP Countries. BFLP, BLP and their affiliates do not provide investment advice or guarantee the accuracy of prices or information in the Services. Nothing on the Services shall constitute an offering of financial instruments by BFLP, BLP or their affiliates.

Ticker: RBXY IN Equity

Periodicity: Annuals

Currency: INR

Note: Years shown on the report are Fiscal Years

Company: Ranbaxy Laboratories Ltd

Filing: Most Recent

Consolidation Basis: Consolidated Data

By Segment

	Original:2006 A	Original:2007 A	Restated:2008 A	Original:2009 A	Original:2010 A	Restated:2011 A	Original:2012 A	Original:2014 A
For the period ending	2006-12-31	2007-12-31	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2014-3-31
Pharmaceuticals								
Assets	78,757.71	85,729.01	118,051.83	111,704.58	96,724.45			139,901.18
Liabilities	14,294.40	17,890.57	89,170.75	76,438.63	35,276.83			106,021.43
Revenue	61,421.33	69,822.46	74,139.35	75,969.46	89,605.39	99,700.02	122,528.94	
Depreciation and	1,841.90	2,183.40	2,824.68	2,676.11	5,532.66			
Amortization								
Capital Expenditures	-19,727.83	-7,157.79	-5,761.54	-5,682.08	-4,838.53			
Others-Chemicals								
Revenue			0.60	0.90	2.32			
Assets	765.22	15.65	19.48	17.13	18.86			
Depreciation and	0.01	0.01	0.01	0.01	0.01			
Amortization								
Liabilities	411.81	3.21	3.20	0.21	0.18			
Capital Expenditures	-0.01							
Unallocated								
Assets	5,459.01	8,330.86	14,544.27	9,813.55	44,867.91			
Liabilities	44,082.58	48,147.86	479.11	1,662.50	49,639.93			
Capital Expenditures	15,369.70	1,930.53	12.74	461.57				
Deferred Employees								
Compensation Reversal								
Depreciation and	0.97	15.71		-8.17				
Amortization								
Minority Interests								
Liabilities		-570.54	-674.61	-533.22				
Other Income (Including								
Export Incentives, Sundries)								
Revenue	12.73							

The format and content of this report may not be modified or altered (including, but not limited to, via deletion or addition) in any way. The BLOOMBERG PROFESSIONAL service and BLOOMBERG Data are owned and distributed locally by Bloomberg Finance L.P. ("BFLP") and its subsidiaries in all jurisdictions other than Argentina, Bermuda, China, India, Japan and Korea (the "BLP Countries"). BFLP is a wholly-owned subsidiary of Bloomberg L.P. ("BLP"). BLP provides BFLP with all global marketing and operational support and service for the Services and distributes the Services either directly or through a non-BFLP subsidiary in the BLP Countries. BFLP, BLP and their affiliates do not provide investment advice or guarantee the accuracy of prices or information in the Services. Nothing on the Services shall constitute an offering of financial instruments by BFLP, BLP or their affiliates.

Ticker: RBXY IN Equity

Periodicity: Annuals

Currency: INR

Note: Years shown on the report are Fiscal Years

Company: Ranbaxy Laboratories Ltd

Filing: Most Recent

Consolidation Basis: Consolidated Data

	Original:2009 A	%	Original:2010 A	%	Restated:2011 A	%	Original:2012 A	%	Original:2014 A
For the period ending	2009-12-31	2010-12-31	2010-12-31	2011-12-31	2011-12-31	2012-12-31	2012-12-31	2014-3-31	2014-3-31
Revenue	75,970.36	100.00	89,607.71	100.00	99,700.02	100.00	122,528.94		
North America	19,574.98	33.86	30,341.36	37.13	38,348.23	43.18	53,797.74		
India	19,400.42	24.43	21,890.27	22.38	23,111.26	18.74	23,349.92		
Europe	15,896.74	17.21	15,423.78	16.93	17,490.49	16.82	20,958.51		
Rest of the World	14,160.26	9.49	8,499.63	8.13	8,396.41	8.23	10,251.43		
Asia Pacific	6,937.96	7.05	6,320.41	6.87	7,092.63	6.71	8,360.56		
Africa		7.96	7,132.26	8.57	8,850.88	6.32	7,879.11		
Reconciliation					-3,589.88		-2,068.33		
Assets	121,535.26	100.00	141,611.22	100.00	157,201.01	100.00	164,651.99	100.00	139,901.18
India	63,759.22	52.10	73,779.49	52.25	82,136.90	55.89	92,023.52	44.72	53,646.69
Europe	28,542.63	26.47	37,489.45	19.22	30,208.81	19.11	31,466.66	25.49	30,570.26
North America	15,650.02	12.91	18,288.63	19.85	31,208.08	15.20	25,019.71	17.53	21,024.42
Reconciliation									19,948.27
Africa		3.99	5,645.00	4.93	7,749.30	5.31	8,738.29	6.98	8,376.55
Asia Pacific	3,202.75	1.51	2,132.68	1.66	2,614.24	1.78	2,938.78	2.70	3,234.89
Rest of the World	10,380.64	3.02	4,275.97	2.09	3,283.68	2.71	4,465.03	2.58	3,100.10
Capital Expenditures	-5,220.51		-4,838.54		-4,569.64		-4,647.64		
Rest of the World	-562.25	3.10	-150.09	1.15	-52.73	3.54	-164.35		
Asia Pacific	-73.34	3.55	-172.00	1.70	-77.81	4.23	-196.38		
Europe	-758.76	4.79	-231.55	6.18	-282.39	6.01	-279.32		
Africa		10.74	-519.77	5.63	-257.32	7.74	-359.67		
North America	-1,349.60	14.87	-719.36	9.90	-452.42	18.85	-875.97		
India	-2,938.13	62.95	-3,045.77	75.43	-3,446.97	59.64	-2,771.95		
Reconciliation	461.57								

The format and content of this report may not be modified or altered (including, but not limited to, via deletion or addition) in any way. The BLOOMBERG PROFESSIONAL service and BLOOMBERG Data are owned and distributed locally by Bloomberg Finance L.P. ("BFLP") and its subsidiaries in all jurisdictions other than Argentina, Bermuda, China, India, Japan and Korea (the "BLP Countries"). BFLP is a wholly-owned subsidiary of Bloomberg L.P. ("BLP"). BLP provides BFLP with all global marketing and operational support and service for the Services and distributes the Services either directly or through a non-BFLP subsidiary in the BLP Countries. BFLP, BLP and their affiliates do not provide investment advice or guarantee the accuracy of prices or information in the Services. Nothing on the Services shall constitute an offering of financial instruments by BFLP, BLP or their affiliates.